Paroxetine

Paroxetine
Clinical data
Pronunciation/pərˈɑːksəˌtin/
pər-AHK-sə-TEEN
Trade namesPaxil, others
AHFS/Drugs.comMonograph
MedlinePlusa698032
License data
Pregnancy
category
  • AU: D
Routes of
administration
By mouth
Drug classSelective serotonin reuptake inhibitor (SSRI)
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class C1 (Other controlled substances)
  • CA: ℞-only
  • UK: POM (Prescription only)
  • US: ℞-only
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability50%
Protein binding93–95%
MetabolismExtensive, liver (mostly CYP2D6-mediated)
Elimination half-life21 hours
ExcretionKidney (64%; 2% unchanged and 62% as metabolites), faecal (36%; <1% unchanged)
Identifiers
  • (3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.112.096
Chemical and physical data
FormulaC19H20FNO3
Molar mass329.371 g·mol−1
3D model (JSmol)
  • c1cc(ccc1[C@@H]2CCNC[C@H]2COc3ccc4c(c3)OCO4)F
  • InChI=1S/C19H20FNO3/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18/h1-6,9,14,17,21H,7-8,10-12H2/t14-,17-/m0/s1 checkY
  • Key:AHOUBRCZNHFOSL-YOEHRIQHSA-N checkY
 X markNcheckY (what is this?)  (verify)

Paroxetine, sold under the brand name Paxil among others, is an antidepressant medication of the selective serotonin reuptake inhibitor (SSRI) class used to treat major depressive disorder, obsessive–compulsive disorder (OCD), panic disorder, social anxiety disorder, post-traumatic stress disorder (PTSD), generalized anxiety disorder, and premenstrual dysphoric disorder. It has also been used in the treatment of premature ejaculation, and hot flashes due to menopause. It is taken orally (by mouth).

Common side effects include drowsiness, dry mouth, loss of appetite, sweating, trouble sleeping, and sexual dysfunction. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that paroxetine's product labeling warn of this risk. Serious side effects may include suicidal thoughts in those under the age of 25, serotonin syndrome, and mania.

Paroxetine was approved for medical use in the United States in 1992 and initially sold by GlaxoSmithKline. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. In 2023, it was the 72nd most commonly prescribed medication in the United States, with more than 9 million prescriptions. In 2018, it was in the top 10 of most prescribed antidepressants in the United States.